Olodaterol comment watch save
BreastfeedingPediatric

  • FDA APPROVAL DATE: 07/31/2014
  • CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
    Adrenergics, Beta blockers, Diuretics, MAO inhibitors, QT interval prolonging agents, Steroids, Tricyclic antidepressants, Xanthine derivatives

Stiolto Respimat is olodaterol and tiotropium.

ASTHMA-RELATED DEATH

See full prescribing information for complete boxed warning.

Please login to view the rest of this drug profile.

Page last updated 07/31/2023

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric

Back to top